Background-Impacts of a single radiofrequency ablation (RFA) on quality of life (QoL) were not well investigated in atrial fibrillation (AF) patients with low stroke risk. Methods and Results-Nine hundred AF patients with low CHADS(2) score (ie, CHADS(2) <= 1) who completed both a baseline and 6-month Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) questionnaire were selected from The Chinese Atrial Fibrillation Registry between 2011 and 2013. A final cohort of 222 patients was constructed after a propensity score matching with 74 in the RFA group and 148 in the non-RFA group. Domains of AFEQT were balanced at baseline between the 2 groups. No statistically significant differences were noted in QoL (all P>0.05) when AFEQT at 6 months was compared between groups, except for the symptoms domain (83.07 +/- 12.37 units in the RFA group vs. 77.68 +/- 17.14 units in the non-RFA group; P=0.008) and treatment satisfaction domain (76.34 +/- 14.92 units in the RFA group vs. 70.38 +/- 16.81 units in the non-RFA group; P=0.01). Within-group changes in all domains and the global score of the questionnaire were moderate to large, whereas between-group comparisons in baseline to 6-month changes and QoL at 6 months were small to moderate according to Cohen effect sizes. Conclusions-QoL was balanced at baseline and improved at 6 months in both groups from this observational propensity-matched cohort based on the AFEQT questionnaire. However, RFA treatment was only associated with small-to-moderate superiorities over non-RFA treatment. The role of RFA in QoL improvement among AF patients with low stroke risk requires further research.
基金:
Ministry of Science and Technology of the People's Republic of ChinaMinistry of Science and Technology, China [2013BAI09B02, 2013DFB30310]; Beijing Municipal Commission of Science and Technology [D11110000 3011004, D131100002313001]; Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support [ZYLX201302]; Bristol-Myers Squibb (BMS)Bristol-Myers Squibb; PfizerPfizer; Johnson JohnsonJohnson & Johnson USA; Boehringer Ingelheim (BI)Boehringer Ingelheim; BayerBayer AG
第一作者机构:[1]Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Natl Clin Res Ctr Cardiovasc Dis, Beijing 100029, Peoples R China;
通讯作者:
通讯机构:[1]Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Natl Clin Res Ctr Cardiovasc Dis, Beijing 100029, Peoples R China;[3]Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, Natl Clin Res Ctr Cardiovasc Dis, 2 Anzhen Rd, Beijing 100029, Peoples R China
推荐引用方式(GB/T 7714):
Bai Ying,Bai Rong,Wu Jia-Hui,et al.Differences in Quality of Life Between Atrial Fibrillation Patients with Low Stroke Risk Treated With and Without Catheter Ablation[J].JOURNAL OF THE AMERICAN HEART ASSOCIATION.2015,4(9):-.doi:10.1161/JAHA.115.002130.
APA:
Bai, Ying,Bai, Rong,Wu, Jia-Hui,Zhang, Ting,Liu, Nian...&Ma, Chang-Sheng.(2015).Differences in Quality of Life Between Atrial Fibrillation Patients with Low Stroke Risk Treated With and Without Catheter Ablation.JOURNAL OF THE AMERICAN HEART ASSOCIATION,4,(9)
MLA:
Bai, Ying,et al."Differences in Quality of Life Between Atrial Fibrillation Patients with Low Stroke Risk Treated With and Without Catheter Ablation".JOURNAL OF THE AMERICAN HEART ASSOCIATION 4..9(2015):-